Production (Stage)
Axsome Therapeutics, Inc.
AXSM
$102.99
-$0.99-0.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -278.27M | -287.22M | -310.96M | -308.55M | -296.38M |
| Total Depreciation and Amortization | 8.26M | 7.96M | 7.63M | 7.31M | 7.00M |
| Total Amortization of Deferred Charges | 2.69M | 2.64M | 2.39M | 2.34M | 2.61M |
| Total Other Non-Cash Items | 118.45M | 114.31M | 143.85M | 120.88M | 119.61M |
| Change in Net Operating Assets | 30.56M | 33.90M | 24.53M | 10.54M | -25.57M |
| Cash from Operations | -118.32M | -128.41M | -132.57M | -167.49M | -192.73M |
| Capital Expenditure | -510.00K | -270.00K | -247.00K | -528.00K | -609.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -510.00K | -270.00K | -247.00K | -528.00K | -609.00K |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 30.00M |
| Total Debt Repaid | -1.23M | -990.00K | -660.00K | -349.00K | -163.00K |
| Issuance of Common Stock | 105.65M | 71.46M | 55.04M | 59.72M | 273.28M |
| Repurchase of Common Stock | -6.67M | -3.95M | -3.70M | -3.58M | -2.59M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9.45M | -8.68M | -7.09M | -9.23M | -22.27M |
| Cash from Financing | 88.30M | 57.84M | 43.59M | 46.56M | 278.26M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -30.53M | -70.84M | -89.22M | -121.46M | 84.93M |